• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CHEN Hui,QIU Lili,DING Juying.Analysis and intervention of the off label use of safflor yellow injection in elderly inpatients[J].Journal Of Pharmaceutical Research,2020,39(5):304-307[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3317times   Download 2977次 QR Code for this article
Scan with your phone!
老年住院患者注射用红花黄色素超说明书用药分析及干预
陈辉1,邱丽丽2,丁菊英2
Font:Larger+|Default|Smaller-
(1.武警特色医学中心药材科,天津 300162;2.胜利油田中心医院药学部,山东 东营 257034)
摘要:
目的 分析老年住院患者注射用红花黄色素超说明书用药情况并干预,降低老年人用药风险,促进临床合理使用。方法 分析老年住院患者注射用红花黄色素超说明书用药现状,通过对其超说明书用药的临床研究和文献进行检索评价后,制定注射用红花黄色素超说明书用药规则,采取软件智能审核与临床药师审核互补的方式对超说明书用药情况进行点评干预。随机抽取2018年1-6月(干预前)和2018年7~12月(干预后)老年住院患者使用注射用红花黄色素病历各480份,评价超说明书用药干预效果。结果 老年住院患者超说明书使用注射用红花黄色素问题严重。涉及的超说明书用药类型主要有超适应症用药、超溶媒、配伍禁忌和超注意事项,干预后各类型超说明书用药例数均明显下降,超说明书用药医嘱比例由干预前的56.61%下降至16.21%,不良反应上报数量由干预前的8例降至干预后的3例。结论 老年住院患者注射用红花黄色素超说明书用药情况普遍存在,利用合理用药软件实时监测与临床药师审核互补的方式可以显著减少超说明书用药。
关键词:  注射用红花黄色素  超说明书用药  老年患者  干预
DOI:10.13506/j.cnki.jpr.2020.05.013
基金项目:山东省中医药科技发展计划项目(No.2015-405、2017-365);东营市中医药重点专科建设项目
Analysis and intervention of the off label use of safflor yellow injection in elderly inpatients
CHEN Hui1,QIU Lili2,DING Juying2
(1.Department of Pharmacy,Characteristic Medical Center of PAP,Tianjin 300162,China;2.Department of Pharmacy,Central Hospital of Shengli Oil Field,Dongying 257034,China)
Abstract:
Objective To analyze and intervene the off-label use of safflor yellow injection in elderly inpatients, and to reduce the risk of drug use and promote its appropriate use.Methods The current situation of the off-label use of safflor yellow injection in elderly inpatients was analyzed. Clinical researches and literature reviews on off-label use of safflor yellow injection were searched and evaluated systematically, and then its reasonable medication rules were developed. To evaluate and intervene the drug use by using a rational drug use software management system audit automatically and clinical pharmacist audit manually. A total of 480 cases of inpatients of safflor yellow injection used from January-June in 2018 (before intervention) and from July-December in 2018 (after intervention) was taken randomly to evaluated the intervention effect on its off-label use.Results Off-label use of safflor yellow injection was serious. The types of off-label use were mainly focused on over indication, over solvent, contraindication and over precaution, after intervention, the situation of off-label use decreased significantly, the proportion of off-label use decreased from 56.61% before intervention to 16.21%, and the number of adverse reactions reported decreased from 8 cases before intervention to 3 cases after intervention.Conclusion Although off-label use of safflor yellow injection was serious, the complementary way of rational drug use software informatized real-time monitoring and clinical pharmacist audited manually may be utilized to reduce the phenomenon.
Key words:  Safflor yellow injection  Off-label usr  Elderly patients  Intervention
Today's Visits:483    Total Visits:2383194
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.